| WB | 1/1000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | Ephrin-B1, EFL-3, ELK ligand, ELK-L, EPH-related receptor tyrosine kinase ligand 2, LERK-2, EFNB1, EFL3, EPLG2, LERK2 |
| Entrez GeneID | 1947 |
| WB Predicted band size | 38.0kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | This EFNB1 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 88-116 amino acids from the Central region of human EFNB1. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是关于EFNB1抗体的3篇模拟参考文献示例(实际文献需通过学术数据库检索获取)：
---
1. **文献名称**: *"Ephrin-B1 Antibody Inhibits Tumor Growth by Blocking Eph Receptor Signaling in Colorectal Cancer"*
**作者**: Smith J, et al.
**摘要**: 研究报道了一种特异性靶向EFNB1的单克隆抗体，通过阻断EFNB1与Eph受体结合，抑制结直肠癌细胞中下游MAPK信号通路的激活，显著减少小鼠移植瘤的生长和转移。
2. **文献名称**: *"Development of a High-Affinity EFNB1 Antibody for Neurodevelopmental Disorder Research"*
**作者**: Lee H, et al.
**摘要**: 该文献描述了一种新型兔源多克隆抗体的开发，验证了其在免疫组化和Western blot中对EFNB1蛋白的特异性识别，并用于研究EFNB1在神经突触形成和颅面发育异常中的作用机制。
3. **文献名称**: *"EFNB1 Antibody-Based Therapeutic Strategy Attenuates Fibrosis in Pulmonary Hypertension"*
**作者**: Chen R, et al.
**摘要**: 研究利用人源化EFNB1中和抗体干预肺动脉高压模型，发现其通过调节血管平滑肌细胞间通讯，减少胶原沉积和血管重塑，为纤维化疾病的治疗提供了新方向。
---
**提示**：实际文献可通过 **PubMed**(https://pubmed.ncbi.nlm.nih.gov/)或 **Google Scholar** 检索关键词(如“EFNB1 antibody”、“Ephrin-B1 therapeutic”)。建议结合研究领域(如癌症、神经科学)筛选近期高影响力论文。
**Background of EFNB1 Antibody**
EFNB1 (Ephrin-B1) is a transmembrane ligand belonging to the Ephrin family, which interacts with Eph receptor tyrosine kinases to mediate bidirectional cell-cell signaling. This protein plays critical roles in developmental processes, including axonal guidance, angiogenesis, cell migration, and tissue boundary formation. Dysregulation of EFNB1 is implicated in various pathologies, such as cancer metastasis, neurodevelopmental disorders, and cardiovascular diseases.
EFNB1 antibodies are immunological tools designed to detect and quantify EFNB1 expression in research and diagnostic settings. These antibodies are widely used in techniques like Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF) to study EFNB1's spatial and temporal distribution in tissues or cultured cells. Monoclonal and polyclonal variants offer specificity for different applications, aiding in elucidating EFNB1's functional mechanisms, such as its involvement in tumor progression via Eph receptor cross-talk or its role in synaptic plasticity.
Recent studies highlight EFNB1's potential as a therapeutic target, particularly in cancers where its overexpression correlates with poor prognosis. Antibodies targeting EFNB1 may also serve as biomarkers for disease stratification or as functional blockers to inhibit pathological signaling pathways. Validation of EFNB1 antibodies for specificity and cross-reactivity remains essential to ensure accuracy in experimental and clinical contexts.
×
